Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATR...
Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In 2007, Omnitrope® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years' safety and effectiveness data for biosimilar rhGH can now be presented.
PATRO Children and PATRO Adults are multicenter, longitudinal, observational, post-marketing surveillance studie...
Alternative Titles
Full title
Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0113b1fccc874933a6019a573b465b77
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0113b1fccc874933a6019a573b465b77
Other Identifiers
ISSN
1472-6823
E-ISSN
1472-6823
DOI
10.1186/s12902-020-0535-4
